Vigabatrin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Vigabatrin
- Vigabatrin: From Infantile Spasms to ARX-Related X-Linked Intellectual Disability with Seizures
Vigabatrin: From Infantile Spasms to ARX-Related X-Linked Intellectual Disability with Seizures
One-Sentence Summary
Vigabatrin is an irreversible GABA-transaminase inhibitor already established as standard therapy for infantile spasms (West syndrome) and certain refractory epilepsies. The TxGNN model predicts it may be effective for ARX-related X-linked intellectual disability with or without seizures, with a prediction score of 98.66%, though currently no clinical trials and only 16 indirect publications (disease natural history, genotype-phenotype reviews, and case reports) support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally documented in the regulatory data provided; per the evidence pack’s mechanistic rationale, Vigabatrin’s established use is infantile spasms (West syndrome) and refractory epilepsy via GABA-transaminase inhibition |
| Predicted New Indication | ARX-related X-linked intellectual disability with or without seizures |
| TxGNN Prediction Score | 98.66% |
| Evidence Level | L4 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed structured mechanism-of-action data for Vigabatrin was flagged as a data gap in this evidence pack. However, the model’s own mechanistic rationale confirms that Vigabatrin is an irreversible inhibitor of GABA-transaminase, which raises brain GABA concentrations and is already standard treatment for infantile spasms (West syndrome).
ARX gene mutations cause abnormal migration and differentiation of GABAergic interneurons, and clinically this frequently presents as infantile spasms and other treatment-resistant seizure phenotypes alongside intellectual disability. Since Vigabatrin’s approved mechanism directly targets the GABAergic pathway implicated in ARX-related disease, there is a plausible pharmacological rationale for its use in the seizure component of this syndrome.
That said, all 16 supporting publications describe disease natural history, genotype-phenotype correlations, or general antiepileptic drug guidelines — none report direct efficacy data for Vigabatrin specifically in ARX-related X-linked intellectual disability. Vigabatrin also carries a known risk of irreversible peripheral visual field constriction, which requires careful risk-benefit evaluation in a pediatric population that may need long-term treatment.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38703411 | 2024 | Review | Molecular Genetics and Metabolism | Updated clinical/molecular review of ALG13-CDG; epileptic spasms are a common presenting symptom, overlapping with ARX-related phenotypes |
| 23400943 | 2013 | Review | Pharmacotherapy | Summarizes antiepileptic drug data across neurogenetic seizure disorders, providing context for GABA-modulating therapy in this disease group |
| 38409029 | 2024 | Review/Guideline | Orphanet Journal of Rare Diseases | International seizure-management guidelines for Rett syndrome and tuberous sclerosis complex, informative for GABA-related epilepsy phenotypes |
| 18462864 | 2008 | Review | Clinical Neurology and Neurosurgery | Describes the phenotypic spectrum of ARX mutations, including infantile spasms and severe intellectual disability |
| 26365141 | 2015 | Review | Current Pharmaceutical Design | Reviews GABAergic neurobiology of Fragile X spectrum disorder and targeted treatment trials, relevant to the GABA-modulation rationale |
| 35545418 | 2022 | Case Report | J Central South Univ (Medical Sciences) | Two pediatric cases of NEXMIF-related X-linked intellectual disability with epilepsy, illustrating the overlapping XLID-epilepsy phenotype |
| 31867230 | 2019 | Case Report/Series | Quantitative Imaging in Medicine and Surgery | Fetal/neonatal MRI findings in ARX-related lissencephaly presenting with neonatal refractory seizures |
| 41004695 | 2025 | Case Report | Neurology | Vigabatrin-associated MRI brain changes and acute obstructive hydrocephalus in an infant treated with Vigabatrin for hypsarrhythmia due to LIS1-related lissencephaly — a directly relevant Vigabatrin safety signal in a related neurogenetic epilepsy syndrome |
| 36436329 | 2023 | Case Report | Pediatric Neurology | Partial efficacy of Vigabatrin in an infant with West syndrome due to pyruvate dehydrogenase complex deficiency, supporting Vigabatrin use in genetic infantile spasm syndromes |
| 21344176 | 2012 | Commentary | Amino Acids | Discusses whether GABA-transaminase inhibitors (Vigabatrin’s pharmacological class) may improve stereotyped behaviors in Rett syndrome |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link between Vigabatrin’s GABA-transaminase inhibition and the GABAergic pathology of ARX-related disease is biologically plausible, but no clinical trials and no direct efficacy studies of Vigabatrin in this specific rare disease population currently exist — evidence is limited to disease-description literature (L4).
To proceed, the following is needed:
- TFDA/EMA label warnings and contraindications (currently a blocking data gap, required before any safety pre-screening)
- Confirmed structured mechanism-of-action documentation for Vigabatrin (currently a data gap)
- Direct clinical or case-series evidence of Vigabatrin use specifically in ARX-related X-linked intellectual disability with seizures
- A pediatric safety monitoring plan addressing Vigabatrin’s known risk of irreversible peripheral visual field defects, given the likely need for long-term use in this population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.